NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced the appointment of David Wambeke as Chief Business Officer, effective March 1, 2026. In conjunction with his new role, Wambeke purchased 1,000,000 shares of NeuroOne common stock at $0.6704 per share, the closing price on February 27, 2026. The insider purchase, valued at approximately $670,400, aligns his interests with shareholders and demonstrates strong conviction in the company's strategic direction.
Wambeke will lead NeuroOne's drug delivery program, working closely with the executive team to advance clinical development and commercialization. His responsibilities include refining product requirements for preclinical and clinical-stage devices, expanding relationships with key opinion leaders, and engaging prospective pharmaceutical partners. He will also oversee investor relations to strengthen market communication and support strategic business development initiatives, including partnerships and corporate transactions.
“David brings a rare combination of public company experience, capital markets expertise, and a demonstrated ability to translate strategic vision into operational and clinical execution,” said Dave Rosa, CEO of NeuroOne. “As we continue to execute on our strategy and expand awareness of NeuroOne’s technology platform, we believe David will be instrumental in sharpening our messaging, deepening investor engagement, and advancing business development activities that support long-term value creation.”
Wambeke previously served as Chief Business Officer at DiaMedica Therapeutics, where he led the expansion of a lead biologic into preeclampsia, overseeing a first-in-pregnancy Phase 2 trial that delivered positive results. Prior to DiaMedica, he spent 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising on equity financings, M&A, and strategic transactions. He began his career in the U.S. Army, was wounded in combat in Baghdad, and awarded the Purple Heart.
“I’m excited to join NeuroOne at such a pivotal moment and to meaningfully align myself with shareholders through my investment,” said Wambeke. “With four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, NeuroOne has validated its platform technology and established a strong commercial foundation in epilepsy and trigeminal nerve applications. As the Company continues to scale commercialization across these cleared indications, I believe even greater opportunities lie ahead in basivertebral ablation, drug delivery, and spinal cord stimulation.”
NeuroOne also granted Wambeke an inducement stock option to purchase 500,000 shares at the same $0.6704 exercise price, vesting over four years. The net proceeds from the share sale will support clinical and product development activities, as well as working capital. The company has four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System, and OneRF® Trigeminal Nerve Ablation System. For more information, visit nmtc1.com.
This appointment and insider purchase come as NeuroOne scales commercialization and explores new applications in basivertebral nerve ablation and spinal cord stimulation. The company's drug delivery program, now under Wambeke's leadership, aims to maximize strategic value through partnerships and clinical advancements.
